Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Stock Information for Marker Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marker Therapeutics Inc.

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.